Mineralys Cash And Short Term Investments vs Common Stock Shares Outstanding Analysis

MLYS Stock

13.67 0.48 3.39%

Mineralys Therapeutics, financial indicator trend analysis is infinitely more than just investigating Mineralys Therapeutics, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Mineralys Therapeutics, is a good investment. Please check the relationship between Mineralys Therapeutics, Cash And Short Term Investments and its Common Stock Shares Outstanding accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

Cash And Short Term Investments vs Common Stock Shares Outstanding

Cash And Short Term Investments vs Common Stock Shares Outstanding Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Mineralys Therapeutics, Cash And Short Term Investments account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Mineralys Therapeutics,'s Cash And Short Term Investments and Common Stock Shares Outstanding is 0.44. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Mineralys Therapeutics, Common, assuming nothing else is changed. The correlation between historical values of Mineralys Therapeutics,'s Cash And Short Term Investments and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Mineralys Therapeutics, Common are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Cash And Short Term Investments i.e., Mineralys Therapeutics,'s Cash And Short Term Investments and Common Stock Shares Outstanding go up and down completely randomly.

Correlation Coefficient

0.44

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Mineralys Therapeutics, balance sheet. This account contains Mineralys Therapeutics, investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Mineralys Therapeutics, Common fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Most indicators from Mineralys Therapeutics,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Mineralys Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

At this time, Mineralys Therapeutics,'s Selling General Administrative is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 129.9 M in 2025, whereas Enterprise Value Over EBITDA is likely to drop (2.86) in 2025.

	2022	2024	2025 (projected)
Interest Expense	1.7M	1.9M	2.0M
Depreciation And Amortization	228.5K	43K	40.9K

Interest Expense Depreciation And Amortization

Mineralys Therapeutics, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Deferred Long Term Liab
Total Assets		-0.48	0.94	0.93	0.86	-0.92	-0.83	-0.8	0.25	0.85	0.63	0.31	-0.85	1.0	0.43	0.97	0.87	0.27	0.85	-0.48	1.0	0.91	1.0	-0.48	0.91	0.92
Short Long Term Debt Total	-0.48		-0.59	-0.62	-0.67	0.53	0.76	0.88	0.03	-0.57	-0.01	-0.05	0.55	-0.49	-0.79	-0.41	-0.83	0.04	-0.67	1.0	-0.49	-0.56	-0.48	1.0	-0.56	-0.69
Other Current Liab	0.94	-0.59		0.97	0.8	-0.93	-0.9	-0.88	0.26	0.92	0.52	0.32	-0.92	0.94	0.64	0.86	0.88	0.3	0.79	-0.59	0.94	0.91	0.94	-0.59	0.91	0.91
Total Current Liabilities	0.93	-0.62	0.97		0.83	-0.85	-0.9	-0.91	0.15	0.93	0.45	0.27	-0.8	0.93	0.72	0.85	0.91	0.2	0.82	-0.62	0.93	0.95	0.92	-0.62	0.95	0.91
Total Stockholder Equity	0.86	-0.67	0.8	0.83		-0.69	-0.68	-0.85	-0.21	0.61	0.2	-0.14	-0.64	0.86	0.45	0.9	0.94	-0.21	1.0	-0.67	0.86	0.92	0.86	-0.67	0.92	0.77
Net Tangible Assets	-0.92	0.53	-0.93	-0.85	-0.69		0.92	0.78	-0.54	-0.91	-0.76	-0.56	0.97	-0.92	-0.48	-0.84	-0.79	-0.55	-0.67	0.53	-0.92	-0.74	-0.92	0.53	-0.74	-0.96
Net Debt	-0.83	0.76	-0.9	-0.9	-0.68	0.92		0.91	-0.45	-0.96	-0.58	-0.54	0.88	-0.84	-0.77	-0.7	-0.87	-0.47	-0.67	0.76	-0.83	-0.75	-0.83	0.76	-0.75	-0.97
Retained Earnings	-0.8	0.88	-0.88	-0.91	-0.85	0.78	0.91		-0.05	-0.83	-0.24	-0.15	0.77	-0.8	-0.82	-0.72	-0.97	-0.07	-0.85	0.88	-0.8	-0.86	-0.8	0.88	-0.86	-0.88
Accounts Payable	0.25	0.03	0.26	0.15	-0.21	-0.54	-0.45	-0.05		0.5	0.85	0.97	-0.5	0.25	0.08	0.11	-0.01	0.99	-0.22	0.03	0.24	-0.11	0.25	0.03	-0.11	0.43
Cash	0.85	-0.57	0.92	0.93	0.61	-0.91	-0.96	-0.83	0.5		0.66	0.6	-0.86	0.86	0.73	0.71	0.78	0.54	0.59	-0.57	0.85	0.77	0.85	-0.57	0.77	0.93
Non Current Assets Total	0.63	-0.01	0.52	0.45	0.2	-0.76	-0.58	-0.24	0.85	0.66		0.86	-0.65	0.63	0.03	0.55	0.29	0.85	0.19	-0.01	0.63	0.28	0.64	-0.01	0.28	0.67
Non Currrent Assets Other	0.31	-0.05	0.32	0.27	-0.14	-0.56	-0.54	-0.15	0.97	0.6	0.86		-0.49	0.32	0.22	0.15	0.08	0.98	-0.15	-0.05	0.31	0.0	0.31	-0.05	0.0	0.51
Other Assets	-0.85	0.55	-0.92	-0.8	-0.64	0.97	0.88	0.77	-0.5	-0.86	-0.65	-0.49		-0.85	-0.5	-0.77	-0.75	-0.52	-0.63	0.55	-0.85	-0.7	-0.85	0.55	-0.7	-0.89
Cash And Short Term Investments	1.0	-0.49	0.94	0.93	0.86	-0.92	-0.84	-0.8	0.25	0.86	0.63	0.32	-0.85		0.44	0.97	0.87	0.28	0.85	-0.49	1.0	0.91	1.0	-0.49	0.91	0.93
Common Stock Shares Outstanding	0.43	-0.79	0.64	0.72	0.45	-0.48	-0.77	-0.82	0.08	0.73	0.03	0.22	-0.5	0.44		0.27	0.68	0.13	0.44	-0.79	0.44	0.59	0.43	-0.79	0.59	0.62
Other Current Assets	0.97	-0.41	0.86	0.85	0.9	-0.84	-0.7	-0.72	0.11	0.71	0.55	0.15	-0.77	0.97	0.27		0.83	0.12	0.89	-0.41	0.97	0.89	0.97	-0.41	0.89	0.83
Other Stockholder Equity	0.87	-0.83	0.88	0.91	0.94	-0.79	-0.87	-0.97	-0.01	0.78	0.29	0.08	-0.75	0.87	0.68	0.83		0.0	0.94	-0.83	0.87	0.91	0.87	-0.83	0.91	0.89
Total Liab	0.27	0.04	0.3	0.2	-0.21	-0.55	-0.47	-0.07	0.99	0.54	0.85	0.98	-0.52	0.28	0.13	0.12	0.0		-0.22	0.04	0.26	-0.06	0.27	0.04	-0.06	0.44
Net Invested Capital	0.85	-0.67	0.79	0.82	1.0	-0.67	-0.67	-0.85	-0.22	0.59	0.19	-0.15	-0.63	0.85	0.44	0.89	0.94	-0.22		-0.67	0.86	0.92	0.85	-0.67	0.92	0.76
Short Long Term Debt	-0.48	1.0	-0.59	-0.62	-0.67	0.53	0.76	0.88	0.03	-0.57	-0.01	-0.05	0.55	-0.49	-0.79	-0.41	-0.83	0.04	-0.67		-0.49	-0.56	-0.48	1.0	-0.56	-0.69
Total Current Assets	1.0	-0.49	0.94	0.93	0.86	-0.92	-0.83	-0.8	0.24	0.85	0.63	0.31	-0.85	1.0	0.44	0.97	0.87	0.26	0.86	-0.49		0.91	1.0	-0.49	0.91	0.92
Capital Stock	0.91	-0.56	0.91	0.95	0.92	-0.74	-0.75	-0.86	-0.11	0.77	0.28	0.0	-0.7	0.91	0.59	0.89	0.91	-0.06	0.92	-0.56	0.91		0.91	-0.56	1.0	0.79
Net Working Capital	1.0	-0.48	0.94	0.92	0.86	-0.92	-0.83	-0.8	0.25	0.85	0.64	0.31	-0.85	1.0	0.43	0.97	0.87	0.27	0.85	-0.48	1.0	0.91		-0.48	0.91	0.92
Short Term Debt	-0.48	1.0	-0.59	-0.62	-0.67	0.53	0.76	0.88	0.03	-0.57	-0.01	-0.05	0.55	-0.49	-0.79	-0.41	-0.83	0.04	-0.67	1.0	-0.49	-0.56	-0.48		-0.56	-0.69
Common Stock	0.91	-0.56	0.91	0.95	0.92	-0.74	-0.75	-0.86	-0.11	0.77	0.28	0.0	-0.7	0.91	0.59	0.89	0.91	-0.06	0.92	-0.56	0.91	1.0	0.91	-0.56		0.79
Deferred Long Term Liab	0.92	-0.69	0.91	0.91	0.77	-0.96	-0.97	-0.88	0.43	0.93	0.67	0.51	-0.89	0.93	0.62	0.83	0.89	0.44	0.76	-0.69	0.92	0.79	0.92	-0.69	0.79

Click cells to compare fundamentals

Mineralys Therapeutics, Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mineralys Stock Analysis

When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Mineralys Cash And Short Term Investments vs Common Stock Shares Outstanding Analysis

Cash And Short Term Investments vs Common Stock Shares Outstanding

Cash And Short Term Investments vs Common Stock Shares Outstanding Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Common Stock Shares Outstanding

Mineralys Therapeutics, fundamental ratios Correlations

Mineralys Therapeutics, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Mineralys Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Short Long Term Debt	+ 1.0	Short Long Term Debt Total
Short Term Debt	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity

Other Stockholder Equity	- 0.97	Retained Earnings
Deferred Long Term Liab	- 0.97	Net Debt
Cash	- 0.96	Net Debt
Deferred Long Term Liab	- 0.96	Net Tangible Assets
Net Tangible Assets	- 0.93	Other Current Liab
Net Working Capital	- 0.92	Net Tangible Assets